HighTower Advisors
TARS icon

HighTower Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

HighTower Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Sell
3,410
-20
-0.6% -$1.28K ﹤0.01% 3488
2026
Q1 		$241K Sell
3,430
-194
-5% -$13.6K ﹤0.01% 3348
2025
Q4 		$297K Sell
3,624
-65
-2% -$4.85K ﹤0.01% 3056
2025
Q3 		$219K Buy
+3,689
New +$182K ﹤0.01% 3296
2025
Q1 		– Sell
-3,734
Closed -$207K – 4043
2024
Q4 		$207K Buy
+3,734
New +$170K ﹤0.01% 3175

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HighTower Advisors's TARS Position: Q2 2026 in Review

HighTower Advisors reduced its Tarsus Pharmaceuticals (TARS) stake by 0.58% in Q2 2026, selling an estimated $1.28K and leaving 3,410 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #3488.

HighTower Advisors first reported a position in TARS in Q4 2024 and has held it in 5 quarters since. The position peaked at $297K in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • HighTower Advisors held 3,410 shares of Tarsus Pharmaceuticals worth $215K as of Q2 2026.
  • HighTower Advisors sold 20 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.28K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3488 holding.
  • HighTower Advisors first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • HighTower Advisors's Tarsus Pharmaceuticals position peaked at $297K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.